BBP
·NYSE
--
--(--)
--
--(--)
Key Stats
Assets Under Management
44.55MUSD
Fund Flows (1Y)
10.61MUSD
Dividend Yield
--
Discount/Premium to NAV
0.11%
Shares Outstanding
550.00K
Expense Ratio
0.79%
About Virtus LifeSci Biotech Products ETF
Issuer
Virtus Investment Advisers, LLC
Brand
Virtus
Home Page
Inception Date
Dec 16, 2014
Structure
Open-Ended Fund
Index Tracked
LifeSci Biotechnology Products Index
Management Style
Passive
Dividend Treatment
Distributes
Distribution Tax Treatment
Qualified dividends
Income Tax Type
Capital Gains
Max ST Capital Gains Rate
39.60%
Max LT Capital Gains Rate
20.00%
Primary Advisor
Virtus Advisers LLC
Distributor
VP Distributors LLC
BBP offers a different approach to biotech investing by handpicking firms whose lead drugs are on its product stage or those firms that have attained FDA approval for their leading drug. Stocks must earn a majority of their revenue from the research and development and/or marketing and sale of novel drugs or other therapeutics used in the treatment of human diseases. The fund is offered by BioShares alongside launched a sister fund, BBC, which targets biotech firms in the clinical trial stage. The index is reconstituted on a semi-annual basis.
Classification
Asset Class
Equity
Category
Sector
Focus
Health Care
Niche
Biotechnology
Strategy
Equal
Geography
U.S.
Weighting Scheme
Equal
Selection Criteria
Proprietary
Returns
1-Month | 3-Month | YTD | 1-Year | 3-Year | 5-Year | |
|---|---|---|---|---|---|---|
Price Performance | +4.70% | +16.31% | +32.85% | +34.41% | +66.48% | +45.38% |
NAV Total Return | +6.35% | +13.55% | +31.66% | +32.53% | +61.57% | +44.00% |
Ratings
No data is currently available
Ainvest’s AI-powered ETF Scoring Algorithm, built to help retail investors make smarter, data-driven decisions. Leveraging deep learning, reinforcement learning, and large language models, the algorithm scores ETFs across five key dimensions: Fund Flow, Momentum, Safety, Fundamentals, and Performance. Each factor is weighted by its correlation to future returns, resulting in a single, actionable score. Backtested over five years with consistently strong predictive accuracy. Ainvest brings institutional-grade artificial intelligence to everyday investors—transforming complexity into clarity with every score.
Holdings Analysis
Sector
Healthcare
100.00%
Healthcare
100.00%
Asset
Region
93%
6.41%
0.59%
Category
Ratio
North America
93.00%
Europe
6.41%
Asia
0.59%
Investment Style
Mega
Large
Medium
Multi
Small
Value
Blend
Growth
Multi-Cap Growth
Comprises companies of multiple sizes that have high growth potential. These ETFs focus on firms across different market caps with promising growth prospects.
Top 10 Holdings
Symbol
Ratio
Amicus Therapeutics Inc
2.09%
Phathom Pharmaceuticals Inc
1.87%
Mirum Pharmaceuticals Inc
1.86%
Moderna Inc
1.78%
BioMarin Pharmaceutical Inc
1.78%
Iovance Biotherapeutics Inc
1.75%
Nuvation Bio Inc
1.74%
Day One Biopharmaceuticals Inc
1.72%
Halozyme Therapeutics Inc
1.68%
Exelixis Inc
1.68%
Top 10 Weight 17.95%
67 Total Holdings
Dividends
Dividend Payout History
Declaration Date | Record Date | Payment Date | Amount |
|---|---|---|---|
| 2017-12-20 | 2017-12-21 | 2017-12-27 | 0.072 |
Premium/Discount Chart
Premium/Discount to NAV
Price
1M
Assets Under Management
Assets Under Management
1M
Fund Flows
Inflows
Outflows
1M
